Phase I/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies

Annals of Nuclear Medicine volume 33, pages119–127(2019)Cite this article

Abstract

Objective

We conducted the present phase I/IIa positron emission tomography (PET) imaging study with 89Zr conjugated with desferroxamine-IAB2M (89Zr-Df-IAB2M), an anti-prostate-specific membrane-antigen minibody, to assess its safety and feasibility in patients with urological cancer.

Methods

89Zr-Df-IAB2M was synthetized by IBA Molecular (Somerset, NJ, USA) and transported by air to Tsukuba Molecular Imaging Center (Tsukuba, Ibaraki, Japan).17 patients received 74 MBq (2 mCi) of 89Zr-Df-IAB2M at total mass doses of 10 mg. Whole-body and plasma clearance, normal-organ and lesion uptake, and radiation absorbed dose were estimated. We also preliminarily tested the performance of 89Zr-immuno-PET imaging for 13 patients with prostate cancer and 4 patients with other urological cancer.

Results

The administration of 89Zr-Df-IAB2M was well-tolerated, and no infusion-related reactions were observed in any patient. No adverse events were noted in the laboratory parameters, vital signs, or other parameters. The plasma clearance was biphasic, with an initial rapid phase (t 1/2 fast: 10.1 ± 3.4 h) followed by a slow phase (t 1/2 slow: 49.0 ± 22.7 h). The half-life of radioactivity in the whole body (WB t1/2) was 237 ± 9 h. The highest absorbed radiation dose was 1.67 mGy/MBq, observed in the liver and kidney. The effective dose was 0.68 ± 0.08 mSv/MBq. The radiation dose rate at 0.5 m distance from the patient was 8.67 µSv/h on day 1, and decreased to 2.26 µSv/h at 5 days after injection. Both bone and lymph node metastases were detected with 89Zr-Df-IAB2M by 24 or 48 h imaging.

Conclusions

Administration of 89Zr-Df-IAB2M was well-tolerated and safe in terms of adverse events and radiation exposure and protection. 89Zr-Df-IAB2M is feasible for usage by long-distance transportation. Further studies are warranted for analysis of its use for tumor lesion detection (UMIN000015356).

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Lubberink M, Herzog H. Quantitative imaging of 124I and 86Y with PET. Eur J Nucl Med Mol Imaging. 2011;38(Suppl 1):10–8.

    Article  PubMed Central  Google Scholar 

  3. 3.

    Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GAMS. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271–81.

    CAS  PubMed  Google Scholar 

  4. 4.

    Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645–68.

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39.

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    Grant CL, Caromile LA, Durrani K, Rahman MM, Claffey KP, Fong GH, et al. Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization. PLoS One. 2012;7:e41285.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Olafsen T, Sirk SJ, Olma S, Shen CK-F, Wu AM. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumor Biol. 2012;33:669–77.

    Article  CAS  Google Scholar 

  8. 8.

    Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE. Folate hydrolaseã (prostate-specific membrane [corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Mod Pathol. 2011;14:1521–9.

    Article  CAS  Google Scholar 

  9. 9.

    Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol. 2012;30:3884–92.

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med. 2009;50:2–5.

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Wu AM. Engineered antibodies for molecular imaging of cancer. Methods. 2014;65:139–47.

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 2008;14:191–7.

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Pandit-Taskar N, O’Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, et al. First-in-human imaging with 89Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake. J Nucl Med. 2016;57:1858–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Jauw YWS, Menke-van der Houven van Oordt CW, Hoekstra OS, Hendrikse NH, Vugts DJ, Zijlstra JM, et al. Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials? Front Pharmacol. 2016;7:131.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. Nucl Med. 2005;46:1023–7.

    Google Scholar 

  16. 16.

    1990 Recommendations of the International Commission on Radiological Protection (1991) ICRP Publication 60. Ann ICRP 21:1–201.

    Article  Google Scholar 

  17. 17.

    Jadvar H, Connolly LP, Fahey FH, Shulkin BL. PET and PET/CT in pediatric oncology. Semin Nucl Med. 2007;37:316–31.

    Article  PubMed  Google Scholar 

  18. 18.

    Matsuda M, Ishikawa E, Yamamoto T, Hatano K, Joraku A, Iizumi Y, et al. Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody. J Neuro-Oncol. 2018;138:581–9.

    Article  CAS  Google Scholar 

  19. 19.

    Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, et al. PSA-stratified performance of 18F- and 68 Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2017;58:947–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to offer special thanks to Professor Motohiro Sato, who is no longer with us, for his great contribution to this work. We wish to thank the members of the Tsukuba Clinical Research and Development Organization (T-CReDO) for their critical advice in conducting the study and data management during the study period. Members of Tsukuba Molecular Imaging Center also deserve credit for carrying out PET imaging.

Author information

Affiliations

  1. Department of Urology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

    Akira Joraku, Koji Kawai, Shuya Kandori, Takahiro Kojima & Hiroyuki Nishiyama

  2. Department of Applied Molecular Imaging, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

    Kentaro Hatano

  3. Department of Radiation Oncology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

    Nobuyoshi Fukumitsu

  4. Department of Medical Physics, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

    Tomonori Isobe & Yutaro Mori

  5. Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo, 173-0015, Japan

    Muneyuki Sakata

  6. Department of Diagnostic and Interventional Radiology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

    Tadashi Hara, Katsuhiro Nasu & Manabu Minami

  7. Tsukuba Clinical Research and Development Organization, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

    Yuichi Iizumi

Authors
  1. Akira Joraku
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kentaro Hatano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koji Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shuya Kandori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takahiro Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nobuyoshi Fukumitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomonori Isobe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yutaro Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Muneyuki Sakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tadashi Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Katsuhiro Nasu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Manabu Minami
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yuichi Iizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hiroyuki Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroyuki Nishiyama.

Ethics declarations

Conflict of interest

ImaginAb (Los Angeles, CA, USA) covered the manufacturing and shipment costs of 89Zr-Df-IAB2M. Tsukuba University Hospital supported the administration cost of the patients.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Joraku, A., Hatano, K., Kawai, K. et al. Phase I/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies. Ann Nucl Med 33, 119–127 (2019). https://doi.org/10.1007/s12149-018-1312-6

Download citation

Keywords

  • Prostate-specific membrane antigen
  • PET
  • 89Zirconium-labeled tracer
  • Urological cancer
  • Minibody
  • Clinical trial